Targacept (TRGT) 2.46 $TRGT
Biotech Weekly: Here Come The Institutional Holdings Updates
Daniel Ward - at Seeking Alpha - Mon Nov 17, 7:31AM CST
LOXO: 11.13 (-0.92), TRGT: 2.46 (-0.01), BOTA: 2.32 (+0.05), XBI: 183.73 (-0.31), IBB: 306.10 (-3.95), BIOS: 5.91 (-0.12), RGDO: 0.89 (+0.02), EXEL: 1.40 (unch), AMPH: 11.73 (+0.02)
Targacept Management Increases Urgency And Aims For Q4 Strategic Action
Daniel Ward - at Seeking Alpha - Fri Nov 07, 8:39AM CST
TRGT: 2.46 (-0.01), ASMB: 7.35 (-0.09), PRTK: 29.05 (+1.06)
More on Targacept Q3 results
Seeking Alpha - at Seeking Alpha - Wed Nov 05, 10:44AM CST
TRGT: 2.46 (-0.01)
Targacept's (TRGT) CEO Dr. Stephen Hill on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Wed Nov 05, 10:32AM CST
TRGT: 2.46 (-0.01)
Targacept (TRGT) Q3 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Wed Nov 05, 7:25AM CST
TRGT: 2.46 (-0.01)
Targacept beats by $0.08
Seeking Alpha - at Seeking Alpha - Wed Nov 05, 6:41AM CST
TRGT: 2.46 (-0.01)
Targacept Reports Third Quarter 2014 Financial Results
Business Wire - Wed Nov 05, 6:35AM CST
Targacept, Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company advancing NNR Therapeutics(TM), today reported its financial results for the third quarter and nine months ended September 30, 2014.
TRGT: 2.46 (-0.01)
Targacept to Report Third Quarter 2014 Financial Results on November 5, 2014
Business Wire - Wed Oct 29, 7:55AM CDT
Targacept Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company advancing NNR Therapeutics(TM), today announced that it will report financial results for the third quarter of 2014 on Wednesday, November 5, 2014, before the U.S. financial markets open.
TRGT: 2.46 (-0.01)
Targacept's Nine-Year Association with AstraZeneca to End - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Oct 13, 3:00PM CDT
Targacept (TRGT) announced that AstraZeneca (AZN) has terminated their nine-year old collaborative research and license agreement.
MDVN: 106.86 (-1.16), TRGT: 2.46 (-0.01), AZN: 71.80 (-1.80), LGND: 52.52 (-1.37)
CYB, SLH, DAL, SYNA, GBF, TRGT Are Seasonally Ripe To Go Up In the Next Five Weeks
M2 - Wed Oct 01, 3:23AM CDT
BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of WisdomTree Dreyfus Chinese Yuan Fund (NYSE:CYB), Solera Holdings Inc (NYSE:SLH), DELTA AIR LINES INC (NYSE
AL), Synaptics Inc (NASDAQ:SYNA), iShares Barclays Government/Credit Bond Fund (NYSE:GBF), Targacept Inc (NASDAQ:TRGT) and each have a high seasonal probability to go Up in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at:
GBF: 114.11 (+0.31), TRGT: 2.46 (-0.01), SYNA: 66.39 (-0.69), DAL: 47.68 (-0.65), SLH: 48.05 (-0.54), CYB: 25.35 (unch)
Targacept (TRGT) is Oversold: Can It Recover? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Sep 08, 9:47AM CDT
Targacept (TRGT) is Oversold: Can It Recover?
TRGT: 2.46 (-0.01)
Targacept Reports Second Quarter 2014 Financial Results
Business Wire - Wed Aug 06, 6:35AM CDT
Targacept, Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company advancing NNR Therapeutics(TM), today reported its financial results for the second quarter and six months ended June 30, 2014.
TRGT: 2.46 (-0.01)
Targacept to Report Second Quarter 2014 Financial Results on August 6, 2014
Business Wire - Wed Jul 30, 7:30AM CDT
Targacept Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company advancing NNR Therapeutics(TM), today announced it will report financial results for the second quarter of 2014 on Wednesday, August 6, 2014, before the U.S. financial markets open.
TRGT: 2.46 (-0.01)
Hot Stock: Targacept, Shares Drop 25.5% (TRGT)
Comtex SmarTrend(R) - Tue Jul 29, 10:09AM CDT
Targacept (NASDAQ:TRGT) is one of today's worst performing low-priced stocks, down 25.5% to $2.92 on 2.2x average daily volume. Targacept has traded 751,000 shares thus far today, vs. average volume of 345,000 shares per day. The stock has underperformed the Dow (-25.5% to the Dow's 0.3%) and underperformed the S&P 500 (-25.5% to the S&P's 0.1%) during today's trading.
TRGT: 2.46 (-0.01)
Targacept to Discontinue TC-5214 Overactive Bladder Program
Business Wire - Mon Jul 28, 3:35PM CDT
Targacept, Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company advancing NNR Therapeutics(TM), today announced top-line results from a Phase 2b clinical trial of TC-5214 as a treatment for overactive bladder (OAB). In the trial, the high dose of TC-5214 demonstrated mixed results on the co-primary endpoints by providing a statistically significant reduction in micturition frequency (p=0.033) and an improvement that did not reach statistical significance on episodes of urinary incontinence (p=0.379) per 24 hours, after 12 weeks of treatment. As a consequence of these results, Targacept is discontinuing further development of TC-5214 in OAB.
TRGT: 2.46 (-0.01)
Technical Update, Leadership Appointments, Therapy Approvals, Notifications, and Clinical Trial Results - Analyst Notes on Biogen, Medivation, BioMarin, Acorda and Targacept
PR Newswire - Thu Jul 17, 7:40AM CDT
Today, Analysts Review released its analysts' notes regarding Biogen Idec Inc. (NASDAQ: BIIB), Medivation, Inc. (NASDAQ: MDVN), BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), Acorda Therapeutics, Inc. (NASDAQ: ACOR) and Targacept, Inc. (NASDAQ: TRGT). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/4882-100free.
MDVN: 106.86 (-1.16), BIIB: 344.49 (+2.16), BMRN: 91.52 (-1.38), TRGT: 2.46 (-0.01), ACOR: 38.70 (+0.06)
Targacept Down 7.6%, Shares Slide into the Red (TRGT)
Comtex SmarTrend(R) - Tue Jul 15, 11:38AM CDT
Targacept (NASDAQ:TRGT) is one of today's worst performing low-priced stocks, down 7.6% to $4.08 on 1.2x average daily volume. Targacept has traded 318,000 shares thus far today, vs. average volume of 272,000 shares per day. The stock has underperformed the Dow (-7.6% to the Dow's -0.1%) and underperformed the S&P 500 (-7.6% to the S&P's -0.4%) during today's trading.
TRGT: 2.46 (-0.01)
Targacept Phase 2b Clinical Trial in Alzheimer's Disease Does Not Show Superiority of TC-1734 Over Donepezil
Business Wire - Mon Jul 14, 2:06PM CDT
Targacept, Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company developing novel NNR Therapeutics(TM), today announced top-line results from a Phase 2b monotherapy clinical trial of TC-1734 as a treatment for mild to moderate Alzheimer's disease. In the trial, TC-1734 did not meet the objective of showing superiority to donepezil, the marketed medication most often prescribed for Alzheimer's disease, after 52 weeks of treatment. The trial did not include a placebo arm and was not designed to determine whether TC-1734 is equivalent to donepezil. The co-primary endpoints for the study were measures of cognitive function and global function. Consistent with previous clinical results, TC-1734 exhibited a benign safety and tolerability profile.
TRGT: 2.46 (-0.01)
Age Related Memory Impairment Clinical Trials Review, H1, 2014
M2 - Mon Jun 30, 10:08AM CDT
Research and Markets (http://www.researchandmarkets.com/research/tn8pmb/age_related) has announced the addition of the "Age Related Memory Impairment Global Clinical Trials Review, H1, 2014" report to their offering. Age Related Memory Impairment Global Clinical Trials Review, H1, 2014" provides data on the Age Related Memory Impairment clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Age Related Memory Impairment. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Age Related Memory Impairment. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Top Companies/Institutions Participating in Age Related Memory Impairment Therapeutics Clinical Trials - Orexo AB - Helicon Therapeutics, Inc. - Dart NeuroScience LLC - Targacept, Inc. - Martek Biosciences Corporation (Inactive) - Lexicon Pharmaceuticals, Inc. - Bayer AG - Allergan, Inc. - Accera, Inc. - Central Drug Research Institute - University of Cincinnati - The University of Arizona - University Hospital, Toulouse - University of California, Los Angeles - University of Southern California - National Institute on Aging - Queen's University - Stanford University - University of Florida For more information visit http://www.researchandmarkets.com/research/tn...ge_related
AGN: 208.47 (-2.67), TRGT: 2.46 (-0.01), LXRX: 0.85 (-0.05)
Targacept Initiates Exploratory Study of TC-6499 in Diabetic Gastroparesis
Business Wire - Wed Jun 25, 7:55AM CDT
Targacept, Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company developing novel NNR Therapeutics(TM), today announced the initiation of a Phase 1/2 exploratory study of TC-6499 as a treatment for gastroparesis, a chronic disorder that slows or stops the passage of food from the stomach to the small intestine. TC-6499 is a novel small molecule that modulates the activity of the alpha3beta4 and other neuronal nicotinic receptors (NNRs). The alpha3beta4 NNR is located throughout the gastrointestinal tract and, when modulated, is believed to increase cholinergic tone, which in turn leads to increased motility.
TRGT: 2.46 (-0.01)
Biotech Weekly: Here Come The Institutional Holdings Updates
Daniel Ward - at Seeking Alpha - Mon Nov 17, 7:31AM CST
LOXO: 11.13 (-0.92), TRGT: 2.46 (-0.01), BOTA: 2.32 (+0.05), XBI: 183.73 (-0.31), IBB: 306.10 (-3.95), BIOS: 5.91 (-0.12), RGDO: 0.89 (+0.02), EXEL: 1.40 (unch), AMPH: 11.73 (+0.02)
Targacept Management Increases Urgency And Aims For Q4 Strategic Action
Daniel Ward - at Seeking Alpha - Fri Nov 07, 8:39AM CST
TRGT: 2.46 (-0.01), ASMB: 7.35 (-0.09), PRTK: 29.05 (+1.06)
More on Targacept Q3 results
Seeking Alpha - at Seeking Alpha - Wed Nov 05, 10:44AM CST
TRGT: 2.46 (-0.01)
Targacept's (TRGT) CEO Dr. Stephen Hill on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Wed Nov 05, 10:32AM CST
TRGT: 2.46 (-0.01)
Targacept (TRGT) Q3 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Wed Nov 05, 7:25AM CST
TRGT: 2.46 (-0.01)
Targacept beats by $0.08
Seeking Alpha - at Seeking Alpha - Wed Nov 05, 6:41AM CST
TRGT: 2.46 (-0.01)
Targacept Reports Third Quarter 2014 Financial Results
Business Wire - Wed Nov 05, 6:35AM CST
Targacept, Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company advancing NNR Therapeutics(TM), today reported its financial results for the third quarter and nine months ended September 30, 2014.
TRGT: 2.46 (-0.01)
Targacept to Report Third Quarter 2014 Financial Results on November 5, 2014
Business Wire - Wed Oct 29, 7:55AM CDT
Targacept Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company advancing NNR Therapeutics(TM), today announced that it will report financial results for the third quarter of 2014 on Wednesday, November 5, 2014, before the U.S. financial markets open.
TRGT: 2.46 (-0.01)
Targacept's Nine-Year Association with AstraZeneca to End - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Oct 13, 3:00PM CDT
Targacept (TRGT) announced that AstraZeneca (AZN) has terminated their nine-year old collaborative research and license agreement.
MDVN: 106.86 (-1.16), TRGT: 2.46 (-0.01), AZN: 71.80 (-1.80), LGND: 52.52 (-1.37)
CYB, SLH, DAL, SYNA, GBF, TRGT Are Seasonally Ripe To Go Up In the Next Five Weeks
M2 - Wed Oct 01, 3:23AM CDT
BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of WisdomTree Dreyfus Chinese Yuan Fund (NYSE:CYB), Solera Holdings Inc (NYSE:SLH), DELTA AIR LINES INC (NYSE
AL), Synaptics Inc (NASDAQ:SYNA), iShares Barclays Government/Credit Bond Fund (NYSE:GBF), Targacept Inc (NASDAQ:TRGT) and each have a high seasonal probability to go Up in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at: GBF: 114.11 (+0.31), TRGT: 2.46 (-0.01), SYNA: 66.39 (-0.69), DAL: 47.68 (-0.65), SLH: 48.05 (-0.54), CYB: 25.35 (unch)
Targacept (TRGT) is Oversold: Can It Recover? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Sep 08, 9:47AM CDT
Targacept (TRGT) is Oversold: Can It Recover?
TRGT: 2.46 (-0.01)
Targacept Reports Second Quarter 2014 Financial Results
Business Wire - Wed Aug 06, 6:35AM CDT
Targacept, Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company advancing NNR Therapeutics(TM), today reported its financial results for the second quarter and six months ended June 30, 2014.
TRGT: 2.46 (-0.01)
Targacept to Report Second Quarter 2014 Financial Results on August 6, 2014
Business Wire - Wed Jul 30, 7:30AM CDT
Targacept Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company advancing NNR Therapeutics(TM), today announced it will report financial results for the second quarter of 2014 on Wednesday, August 6, 2014, before the U.S. financial markets open.
TRGT: 2.46 (-0.01)
Hot Stock: Targacept, Shares Drop 25.5% (TRGT)
Comtex SmarTrend(R) - Tue Jul 29, 10:09AM CDT
Targacept (NASDAQ:TRGT) is one of today's worst performing low-priced stocks, down 25.5% to $2.92 on 2.2x average daily volume. Targacept has traded 751,000 shares thus far today, vs. average volume of 345,000 shares per day. The stock has underperformed the Dow (-25.5% to the Dow's 0.3%) and underperformed the S&P 500 (-25.5% to the S&P's 0.1%) during today's trading.
TRGT: 2.46 (-0.01)
Targacept to Discontinue TC-5214 Overactive Bladder Program
Business Wire - Mon Jul 28, 3:35PM CDT
Targacept, Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company advancing NNR Therapeutics(TM), today announced top-line results from a Phase 2b clinical trial of TC-5214 as a treatment for overactive bladder (OAB). In the trial, the high dose of TC-5214 demonstrated mixed results on the co-primary endpoints by providing a statistically significant reduction in micturition frequency (p=0.033) and an improvement that did not reach statistical significance on episodes of urinary incontinence (p=0.379) per 24 hours, after 12 weeks of treatment. As a consequence of these results, Targacept is discontinuing further development of TC-5214 in OAB.
TRGT: 2.46 (-0.01)
Technical Update, Leadership Appointments, Therapy Approvals, Notifications, and Clinical Trial Results - Analyst Notes on Biogen, Medivation, BioMarin, Acorda and Targacept
PR Newswire - Thu Jul 17, 7:40AM CDT
Today, Analysts Review released its analysts' notes regarding Biogen Idec Inc. (NASDAQ: BIIB), Medivation, Inc. (NASDAQ: MDVN), BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), Acorda Therapeutics, Inc. (NASDAQ: ACOR) and Targacept, Inc. (NASDAQ: TRGT). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/4882-100free.
MDVN: 106.86 (-1.16), BIIB: 344.49 (+2.16), BMRN: 91.52 (-1.38), TRGT: 2.46 (-0.01), ACOR: 38.70 (+0.06)
Targacept Down 7.6%, Shares Slide into the Red (TRGT)
Comtex SmarTrend(R) - Tue Jul 15, 11:38AM CDT
Targacept (NASDAQ:TRGT) is one of today's worst performing low-priced stocks, down 7.6% to $4.08 on 1.2x average daily volume. Targacept has traded 318,000 shares thus far today, vs. average volume of 272,000 shares per day. The stock has underperformed the Dow (-7.6% to the Dow's -0.1%) and underperformed the S&P 500 (-7.6% to the S&P's -0.4%) during today's trading.
TRGT: 2.46 (-0.01)
Targacept Phase 2b Clinical Trial in Alzheimer's Disease Does Not Show Superiority of TC-1734 Over Donepezil
Business Wire - Mon Jul 14, 2:06PM CDT
Targacept, Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company developing novel NNR Therapeutics(TM), today announced top-line results from a Phase 2b monotherapy clinical trial of TC-1734 as a treatment for mild to moderate Alzheimer's disease. In the trial, TC-1734 did not meet the objective of showing superiority to donepezil, the marketed medication most often prescribed for Alzheimer's disease, after 52 weeks of treatment. The trial did not include a placebo arm and was not designed to determine whether TC-1734 is equivalent to donepezil. The co-primary endpoints for the study were measures of cognitive function and global function. Consistent with previous clinical results, TC-1734 exhibited a benign safety and tolerability profile.
TRGT: 2.46 (-0.01)
Age Related Memory Impairment Clinical Trials Review, H1, 2014
M2 - Mon Jun 30, 10:08AM CDT
Research and Markets (http://www.researchandmarkets.com/research/tn8pmb/age_related) has announced the addition of the "Age Related Memory Impairment Global Clinical Trials Review, H1, 2014" report to their offering. Age Related Memory Impairment Global Clinical Trials Review, H1, 2014" provides data on the Age Related Memory Impairment clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Age Related Memory Impairment. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Age Related Memory Impairment. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Top Companies/Institutions Participating in Age Related Memory Impairment Therapeutics Clinical Trials - Orexo AB - Helicon Therapeutics, Inc. - Dart NeuroScience LLC - Targacept, Inc. - Martek Biosciences Corporation (Inactive) - Lexicon Pharmaceuticals, Inc. - Bayer AG - Allergan, Inc. - Accera, Inc. - Central Drug Research Institute - University of Cincinnati - The University of Arizona - University Hospital, Toulouse - University of California, Los Angeles - University of Southern California - National Institute on Aging - Queen's University - Stanford University - University of Florida For more information visit http://www.researchandmarkets.com/research/tn...ge_related
AGN: 208.47 (-2.67), TRGT: 2.46 (-0.01), LXRX: 0.85 (-0.05)
Targacept Initiates Exploratory Study of TC-6499 in Diabetic Gastroparesis
Business Wire - Wed Jun 25, 7:55AM CDT
Targacept, Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company developing novel NNR Therapeutics(TM), today announced the initiation of a Phase 1/2 exploratory study of TC-6499 as a treatment for gastroparesis, a chronic disorder that slows or stops the passage of food from the stomach to the small intestine. TC-6499 is a novel small molecule that modulates the activity of the alpha3beta4 and other neuronal nicotinic receptors (NNRs). The alpha3beta4 NNR is located throughout the gastrointestinal tract and, when modulated, is believed to increase cholinergic tone, which in turn leads to increased motility.
TRGT: 2.46 (-0.01)
